[go: up one dir, main page]

MX2010008025A - Anticuerpos ron y usos de los mismos. - Google Patents

Anticuerpos ron y usos de los mismos.

Info

Publication number
MX2010008025A
MX2010008025A MX2010008025A MX2010008025A MX2010008025A MX 2010008025 A MX2010008025 A MX 2010008025A MX 2010008025 A MX2010008025 A MX 2010008025A MX 2010008025 A MX2010008025 A MX 2010008025A MX 2010008025 A MX2010008025 A MX 2010008025A
Authority
MX
Mexico
Prior art keywords
antibodies
ron
fragments
variants
derivatives
Prior art date
Application number
MX2010008025A
Other languages
English (en)
Inventor
Veronique Bailly
Ellen Garber
Christilyn Graff
Heather Huet
Steven Miklasz
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of MX2010008025A publication Critical patent/MX2010008025A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a anticuerpos los cuales se enlazan a RON (receptor de Nantes original, MSTIR), usos de los mismos, en particular en la diagnosis y tratamiento de cáncer. Se proporcionan anticuerpos específicos los cuales inhiben las trayectorias de proliferación de tumor y pro-supervivencia mediada por RON y -variantes, fragmentos y derivados de los mismos. También se proporcionan anticuerpos específicos los cuales bloquean la capacidad del ligando, MSP, para enlazarse a RON, así como también fragmentos, variantes y derivados de tales anticuerpos. La invención también incluye polinucleótidos que codifican los anticuerpos o fragmentos anteriores, variantes o derivados de los mismos, así como también vectores y células hospederas que comprenden tales polinucleótidos. La invención además incluye métodos de diagnóstico y tratamiento de cáncer usando anticuerpos de la invención.
MX2010008025A 2008-01-22 2009-01-22 Anticuerpos ron y usos de los mismos. MX2010008025A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2277908P 2008-01-22 2008-01-22
PCT/US2009/000376 WO2009094148A2 (en) 2008-01-22 2009-01-22 Ron antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2010008025A true MX2010008025A (es) 2010-08-04

Family

ID=40901578

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010008025A MX2010008025A (es) 2008-01-22 2009-01-22 Anticuerpos ron y usos de los mismos.

Country Status (11)

Country Link
US (1) US20090226442A1 (es)
EP (1) EP2245066A2 (es)
JP (1) JP2011509687A (es)
KR (1) KR20100106590A (es)
CN (1) CN101977937A (es)
AU (1) AU2009206724A1 (es)
BR (1) BRPI0906498A2 (es)
CA (1) CA2712697A1 (es)
IL (1) IL207129A0 (es)
MX (1) MX2010008025A (es)
WO (1) WO2009094148A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI480050B (zh) 2009-02-10 2015-04-11 Daiichi Sankyo Co Ltd 抗－ｍｓｔ１ｒ抗體及其用途
CN105693861A (zh) * 2009-12-29 2016-06-22 新兴产品开发西雅图有限公司 异二聚体结合蛋白及其应用
MA34004B1 (fr) 2010-01-28 2013-02-01 Glaxo Group Ltd Protéines de liaison à cd127
US9127052B2 (en) 2010-06-29 2015-09-08 Centre National De La Recherche Scientifique LLT-1 antibodies with new functional properties
CA2804399A1 (en) * 2010-07-06 2012-01-12 Aveo Pharmaceuticals, Inc. Anti-ron antibodies
CA2843158A1 (en) 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
BR112014019861A2 (pt) * 2012-02-17 2017-07-04 Seattle Genetics Inc anticorpo, ácido nucleico isolado, método de tratamento de um paciente com câncer, e, composição farmacêutica de um anticorpo
TW201444872A (zh) 2013-03-06 2014-12-01 Merrimack Pharmaceuticals Inc 抗Ｃ－ＭＥＴ串聯Ｆｃ雙特異性抗體
KR102131371B1 (ko) * 2013-07-02 2020-07-08 삼성전자주식회사 Ang-2 특이적 항체 및 그의 용도
CN105504049B (zh) * 2014-09-26 2019-07-05 艾托金生物医药（苏州）有限公司 宫颈癌相关的hpv e7蛋白单克隆抗体及其应用
CN110799211B (zh) 2016-09-08 2024-11-22 美国德州精准药靶有限公司 特异性识别丛蛋白-信号素-整合素结构域的抗ron单克隆抗体的药物呈递作用及其在肿瘤治疗中的应用
US11834506B2 (en) 2017-02-08 2023-12-05 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind NKG2D, CD16, and a tumor-associated antigen for activation of natural killer cells and therapeutic uses thereof to treat cancer
US11884732B2 (en) 2017-02-20 2024-01-30 Dragonfly Therapeutics, Inc. Proteins binding HER2, NKG2D and CD16
DK3749346T3 (da) * 2018-02-08 2024-09-09 Dragonfly Therapeutics Inc Antistof variable domænekombinationer rettet mod nkg2d-receptoren
US12384847B2 (en) * 2018-02-08 2025-08-12 Dragonfly Therapeutics, Inc. Cancer therapy involving an anti-PD1 antibody and a multi-specific binding protein that binds NKG2D, CD16, and a tumor-associated antigen
SG11202007945UA (en) 2018-02-20 2020-09-29 Dragonfly Therapeutics Inc Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
BR112021002276A2 (pt) 2018-08-08 2021-05-04 Dragonfly Therapeutics, Inc. proteínas de ligação a nkg2d, cd16 e um antígeno associado ao tumor
PE20211860A1 (es) 2018-08-08 2021-09-21 Dragonfly Therapeutics Inc Proteinas de union multiespecificas que se unen a bcma, nkg2d y cd16 y metodos de uso
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
JP2022544393A (ja) 2019-08-12 2022-10-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッド マクロファージ刺激１受容体（ｍｓｔ１ｒ）バリアント及びその使用
US12157771B2 (en) 2020-05-06 2024-12-03 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and CLEC12A
EP4301774A4 (en) 2021-03-03 2025-08-13 Dragonfly Therapeutics Inc METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294330B1 (en) * 1997-01-31 2001-09-25 Odyssey Pharmaceuticals Inc. Protein fragment complementation assays for the detection of biological or drug interactions
US20020002276A1 (en) * 1997-02-10 2002-01-03 Genentech, Inc. Chimeric heteromultimer adhesins
WO2000018895A1 (en) * 1998-09-25 2000-04-06 The Children's Medical Center Corporation Short peptides which selectively modulate the activity of protein kinases
WO2002083074A2 (en) * 2001-04-13 2002-10-24 Children's Hospital Medical Center Methods for the treatment of hepatic disorders
WO2002087618A1 (en) * 2001-04-27 2002-11-07 Takeda Chemical Industries, Ltd. Preventive/therapeutic method for cancer
WO2002102972A2 (en) * 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
US6867005B2 (en) * 2001-10-24 2005-03-15 Beckman Coulter, Inc. Method and apparatus for increasing the dynamic range and accuracy of binding assays
EP1468118A4 (en) * 2002-01-31 2006-08-02 Millennium Pharm Inc METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER
DK1675961T3 (da) * 2003-10-24 2009-02-23 Oncalis Ag Fremgangsmåde til identifikation og/eller validering af receptortyrosinkinaseinhibitorer
JP2008508858A (ja) * 2004-05-13 2008-03-27 イムクローン システムズ インコーポレイティド マクロファージ−刺激タンパク質受容体（ｒｏｎ）の阻害
CA2565974A1 (en) * 2004-05-14 2005-12-01 Receptor Biologix, Inc. Cell surface receptor isoforms and methods of identifying and using the same
US20060199226A1 (en) * 2005-03-02 2006-09-07 Schiffer Hans H Functional bioluminescence energy resonance transfer (BRET) assay to screen, identify and characterize receptor tyrosine kinase ligands
BRPI0709598A8 (pt) * 2006-03-17 2019-01-08 Biogen Idec Inc composições de polipeptídeos estabilizados
US7452985B2 (en) * 2006-08-17 2008-11-18 Visgeneer, Inc. Human Ron-related gene variant associated with cancers
AR069393A1 (es) * 2007-11-21 2010-01-20 Imclone Systems Inc Inhibicion del receptor para la proteina estimulante del macrofago (ron) y metodos para el tratamiento del mismo

Also Published As

Publication number Publication date
KR20100106590A (ko) 2010-10-01
IL207129A0 (en) 2010-12-30
EP2245066A2 (en) 2010-11-03
WO2009094148A3 (en) 2010-01-14
AU2009206724A1 (en) 2009-07-30
WO2009094148A2 (en) 2009-07-30
CA2712697A1 (en) 2009-07-30
CN101977937A (zh) 2011-02-16
US20090226442A1 (en) 2009-09-10
BRPI0906498A2 (pt) 2015-07-14
JP2011509687A (ja) 2011-03-31

Similar Documents

Publication Publication Date Title
MX2010008025A (es) Anticuerpos ron y usos de los mismos.
EP1999149A4 (en) ANTI-IGF-1R ANTIBODIES AND USES THEREOF
UA107921C2 (en) Variants of polypeptide of receptor ivr activin and their use
MX2008009886A (es) Anticuerpos que enlazan par-2.
WO2006119365A3 (en) Composition and methods for cancer diagnosis utilizing the mir 17-92 cluster
MX2009009787A (es) Mutaciones de k-ras y terapia con anticuerpos anti-egfr.
MX2009002571A (es) Anticuerpos anti-activina a y usos de los mismos.
WO2009102421A3 (en) Targeted therapeutics based on engineered proteins that bind egfr
WO2008105797A3 (en) Polynucleotides encoding novel pcsk9 variants
BRPI0923786C8 (pt) compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos e composições farmacêuticas compreendendo ditos compostos
MX2009009779A (es) Mutaciones de k-ras y b-raf y terapia con anticuerpos anti-egfr.
IL207637A (en) Choosing a Breast Cancer Remedy Using Antibody-Based Arrays
EA200901436A1 (ru) Антигенсвязывающие белки, связывающие par-2
ATE548389T1 (de) Therapeutische und diagnostische verfahren und zusammensetzungen zum targeting von 4ig-b7-h3 und dem entsprechenden nk-zellen-rezeptor
WO2008018642A3 (en) Genes and polypeptides relating to breast cancers
WO2003061559A3 (en) Binding peptides specific for the extracellular domain of erbb2 and uses therefor
WO2009015050A3 (en) Gene expression profile for predicting ovarian cancer patient survival
WO2005123993A8 (en) Phage microarray profiling of the humoral response to disease
UA99602C2 (ru) Антитело, специфически связывающееся с jam-a, способное ингибировать пролиферацию опухолевых клеток
WO2006116322A3 (en) Nicotinamide riboside kinase compositions and methods for using the same
WO2010033773A3 (en) Diagnostic, prognostic and therapeutic uses of mirs in adaptive pathways and/or disease pathways
TW200626900A (en) Wnt proteins and detection and treatment of cancer
WO2008060945A3 (en) Diagnosis and treatment of breast cancer
TW200626899A (en) Frizzled proteins and detection and treatment of cancer
WO2009027978A8 (en) NUCLEIC ACID SEQUENCES COMPRISING NF-ϰB BINDING SITE WITHIN O(6)-METHYLGUANINE-DNA-METHYLTRANSFERASE (MGMT) PROMOTER REGION AND USES THEREOF FOR THE TREATMENT OF CANCER AND IMMUNE-RELATED DISORDERS

Legal Events

Date Code Title Description
FA Abandonment or withdrawal